What Is Olaparib Used For?
Olaparib is a prescription PARP inhibitor used to treat or help control certain cancers in carefully selected patients. Its use is based on the type of cancer, stage of disease, previous treatments, genetic or molecular characteristics of the tumor, and the specific regulatory indication applicable to the patient.
Olaparib is particularly important in cancers where defects in DNA-repair mechanisms make tumor cells more dependent on PARP-mediated repair pathways.
The medicine may be used as maintenance therapy after a favorable response to previous treatment or as treatment for certain advanced or metastatic cancers.
The two olaparib 150 mg products featured on this website are:
- Olanib 150 mg — Everest Pharmaceuticals Ltd.
- Olakin 150 mg — Ziska Pharmaceuticals Limited
Both contain olaparib 150 mg.
Olaparib for Ovarian Cancer
Olaparib has an important role in the treatment of selected patients with advanced epithelial ovarian cancer and related cancers, including fallopian tube and primary peritoneal cancer.
In certain approved treatment settings, olaparib is used as maintenance therapy after a patient has responded completely or partially to platinum-based chemotherapy.
Maintenance treatment does not mean that olaparib immediately eliminates every remaining cancer cell. Instead, the goal is to suppress cancer-cell growth and delay disease progression for as long as possible.
Some ovarian-cancer indications specifically involve BRCA1/2 mutations. Other treatment settings may involve homologous recombination deficiency or broader genomic characteristics.
The precise eligibility requirements depend on the patient’s treatment history and the applicable regulatory approval.
First-Line Maintenance Treatment
For certain patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, olaparib may be used as maintenance treatment following a response to first-line platinum-based chemotherapy.
Patients with a relevant BRCA mutation may particularly benefit from this treatment approach.
In some approved settings, olaparib is used together with bevacizumab for patients whose tumors meet specified homologous-recombination-deficiency criteria.
The decision to use maintenance olaparib is made after evaluating the patient’s response to chemotherapy and relevant molecular or genetic test results.
Maintenance Treatment for Recurrent Disease
Olaparib may also be used in selected patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer whose disease has responded to platinum-based chemotherapy.
This approach can be especially relevant when the cancer contains an appropriate BRCA mutation.
The oncology team determines whether the patient meets the applicable criteria based on the cancer history, previous platinum treatments, response, genetic findings, and other clinical factors.
Olaparib for Breast Cancer
Olaparib is used in specific patients with HER2-negative breast cancer associated with a harmful or potentially harmful germline BRCA mutation.
It can have a role in both selected early high-risk breast cancer and metastatic breast cancer treatment settings.
High-Risk Early Breast Cancer
For certain adults with HER2-negative, high-risk early breast cancer and a deleterious or suspected deleterious germline BRCA mutation, olaparib may be used as adjuvant treatment after appropriate neoadjuvant or adjuvant chemotherapy.
Adjuvant therapy is treatment given after the primary cancer treatment to reduce the risk of the cancer returning.
Eligibility depends on specific clinical factors, including the patient’s cancer characteristics, BRCA status, previous chemotherapy, and treatment history.
Metastatic Breast Cancer
Olaparib is also used for certain adults with germline BRCA-mutated, HER2-negative metastatic breast cancer.
In this setting, the cancer has spread beyond the original breast or regional area and requires systemic treatment.
Olaparib provides a targeted treatment option for selected patients whose tumors have a BRCA-related DNA-repair vulnerability.
The choice of treatment depends on previous therapies, hormone-receptor status, HER2 status, BRCA findings, disease behavior, and the overall treatment strategy.
Olaparib for Pancreatic Cancer
Olaparib has an approved role in selected patients with metastatic pancreatic adenocarcinoma associated with a germline BRCA1 or BRCA2 mutation in jurisdictions where this indication is approved.
The treatment may be used as maintenance therapy following a response or stable disease after an appropriate period of platinum-based chemotherapy.
This is an important example of how genetic information can influence cancer treatment.
Not every patient with pancreatic cancer has a BRCA mutation, and not every patient with a BRCA mutation will necessarily be suitable for olaparib. Genetic testing and clinical assessment are therefore important when considering this treatment.
Olaparib for Prostate Cancer
Olaparib can be used in certain patients with metastatic castration-resistant prostate cancer (mCRPC) whose cancer contains specific genetic alterations affecting DNA repair.
One established treatment setting involves tumors with BRCA mutations.
In some approved treatment regimens, olaparib is used in combination with abiraterone and prednisone or prednisolone for appropriate patients with BRCA-mutated metastatic castration-resistant prostate cancer.
The treatment of advanced prostate cancer can involve multiple hormonal, targeted, radiotherapeutic, and other systemic therapies. Olaparib is therefore selected according to the patient’s molecular results and previous treatment history.
Olaparib in Other Approved Treatment Settings
Regulatory approvals for olaparib are not identical worldwide.
For example, the European regulatory framework includes additional treatment settings and combinations for selected cancers, including certain endometrial-cancer treatment combinations.
Because cancer-drug approvals can change over time and differ between countries, patients should rely on the prescribing information applicable in their country and the advice of their treating oncology team.
A medicine being approved for one cancer type or treatment combination does not automatically mean that it is approved for another cancer.
Why Genetic Testing Can Be Important
Olaparib is closely associated with the biology of DNA repair.
Depending on the cancer, doctors may order genetic or molecular tests to determine whether the tumor or patient carries characteristics associated with potential sensitivity to PARP inhibition.
Important terms include:
BRCA1 and BRCA2
BRCA1 and BRCA2 are genes involved in repairing damaged DNA.
Harmful mutations can impair DNA repair and create a vulnerability that may be exploited by PARP inhibitors such as olaparib.
Germline Mutation
A germline mutation is a genetic change that is present in the body’s cells and may be inherited.
A germline BRCA result can have implications beyond treatment selection and may lead to recommendations for genetic counseling or testing of relatives.
Somatic Mutation
A somatic mutation is a genetic change acquired by cells during a person’s lifetime. It may be present in the tumor without being present throughout the rest of the body.
Homologous Recombination Deficiency
Homologous recombination deficiency, often abbreviated HRD, describes impairment of an important DNA-repair pathway.
Some olaparib treatment indications use HRD-related criteria when determining eligibility.
The exact tests and definitions depend on the cancer type and regulatory indication.
Olaparib as Maintenance Therapy
Maintenance therapy is one of the most important uses of olaparib.
In maintenance treatment, a patient has already received another cancer therapy—often chemotherapy—and the cancer has responded or is controlled.
Olaparib is then used to help maintain that response and delay progression.
The concept is different from emergency treatment of rapidly progressing disease. Maintenance therapy is part of a planned long-term treatment strategy.
Patients should continue taking olaparib exactly as prescribed even when they feel well, unless their healthcare professional instructs them to stop or modify treatment.
Treatment Benefits of Olaparib
Potential benefits depend on the cancer and the patient’s individual clinical circumstances.
Olaparib may:
- Delay cancer progression in selected treatment settings
- Extend the period during which disease remains controlled
- Provide a targeted treatment option for cancers with specific DNA-repair abnormalities
- Offer an oral alternative to some treatment approaches
- Be used as maintenance treatment after an appropriate response to previous therapy
- Provide treatment options for selected BRCA-mutated cancers
These potential benefits should always be balanced against the possible risks and adverse effects of treatment.
Olaparib is not guaranteed to work for every patient.
How Doctors Decide Whether Olaparib Is Appropriate
Before prescribing olaparib, an oncology team may consider:
- Exact cancer diagnosis
- Stage of disease
- Whether the disease is recurrent, advanced, or metastatic
- Previous chemotherapy
- Response to platinum-based treatment where relevant
- BRCA1/2 status
- Germline versus tumor-specific genetic findings
- HRD or other biomarker information where relevant
- Hormone-receptor and HER2 status for breast cancer
- Previous targeted therapies
- Kidney function
- Complete blood count
- Other medical conditions
- Current medicines
- Potential drug interactions
- Previous adverse reactions
This assessment helps determine whether olaparib is suitable and what dose should be used.
Olaparib Is Not Suitable for Every Cancer Patient
A common misconception is that a PARP inhibitor can be used whenever a patient has cancer.
This is incorrect.
Olaparib is indicated only for specific diseases and treatment circumstances. The presence of a BRCA mutation may be important, but a BRCA mutation alone does not establish eligibility for every olaparib indication.
Similarly, having an ovarian, breast, pancreatic, prostate, or another cancer does not automatically mean olaparib is appropriate.
The treatment decision should be based on the complete clinical picture.
Treatment With Olanib 150 mg or Olakin 150 mg
When a healthcare professional prescribes an olaparib regimen, a 150 mg tablet may be used to achieve the prescribed dose.
For applicable adult tablet indications, the standard recommended dose is commonly 300 mg twice daily, equivalent to two 150 mg tablets per dose. However, dose reductions or alternative dosing may be required in particular circumstances.
For example, patients with moderate renal impairment may require a lower dose.
Patients should never calculate their own dose based only on the strength printed on the package.
A prescription for “olaparib 150 mg” can refer to the tablet strength rather than the total amount to be taken each day.
Taking Olaparib During Cancer Treatment
Olaparib tablets are generally taken twice daily at approximately the same times each day for regimens that use twice-daily tablet dosing.
The tablets can generally be taken with or without food.
Patients should swallow tablets whole with water.
If a dose is forgotten, patients should not take an extra dose to compensate unless specifically instructed by their healthcare professional.
If vomiting occurs after taking a dose, patients should follow their prescribing team’s instructions rather than automatically repeating the dose.
Monitoring During Treatment
Because olaparib can affect the bone marrow, regular blood testing may be necessary.
Healthcare professionals may monitor:
- Hemoglobin and red blood-cell parameters
- White blood-cell counts
- Neutrophils
- Platelets
- Kidney function
- Other laboratory values when clinically appropriate
Monitoring is particularly important when treatment continues for an extended period.
The oncology team may also monitor symptoms, treatment response, other medicines, and overall tolerance.
When Treatment May Need to Be Interrupted
A doctor may temporarily interrupt olaparib or reduce the dose if a patient develops significant adverse effects.
Treatment decisions can depend on the severity and duration of the reaction and whether laboratory abnormalities are present.
Patients should not stop treatment permanently without medical advice.
If severe symptoms occur, the patient should contact the treating healthcare team promptly.
Important Safety Reminder
Olaparib can cause serious adverse reactions, including bone-marrow suppression, myelodysplastic syndrome or acute myeloid leukemia, and pneumonitis.
Patients should promptly report concerning symptoms such as:
- Persistent fever or infection symptoms
- Unusual bruising or bleeding
- Severe or worsening weakness
- Shortness of breath
- New or worsening cough
- Chest discomfort
- Severe or persistent symptoms that are unusual for the patient
Pregnancy precautions are also important because olaparib can cause fetal harm. Patients who can become pregnant should discuss appropriate contraception and pregnancy planning with their healthcare professional.
Breastfeeding should also be discussed before treatment.
Summary of Olaparib Uses
| Cancer / Condition | Selected Treatment Role |
|---|---|
| Ovarian cancer | Maintenance treatment in specified settings, including selected BRCA-mutated or HRD-positive disease |
| Fallopian tube cancer | Maintenance treatment in specified settings |
| Primary peritoneal cancer | Maintenance treatment in specified settings |
| HER2-negative breast cancer | Selected germline BRCA-mutated early high-risk or metastatic disease |
| Metastatic pancreatic adenocarcinoma | Selected germline BRCA-mutated disease in approved maintenance settings |
| Metastatic castration-resistant prostate cancer | Selected patients with relevant DNA-repair mutations, including BRCA-mutated disease |
| Other cancers | Additional indications may exist in particular jurisdictions |
Final Takeaway
Olaparib is a specialized targeted cancer medicine whose usefulness depends heavily on the biology of the cancer and the treatment setting.
Its ability to inhibit PARP-mediated DNA repair can create a therapeutic vulnerability in selected cancers with impaired DNA-repair mechanisms. BRCA1/2 mutations and HRD-related characteristics are therefore important in several olaparib treatment decisions.
Olanib 150 mg and Olakin 150 mg provide branded 150 mg tablet formulations of olaparib. They should be used only according to a qualified healthcare professional’s prescription and the applicable product information.
Patients should not start, stop, substitute, or change the dose of olaparib without consulting their oncology team.